Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer.

Guodong Li,Jiangang Liu

doi:10.1155/2021/2280440

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors with high morbidity and mortality. The early symptoms are latent, and most patients are in the middle or late stage when they are diagnosed. The best opportunity for surgery has been lost, and surgical resection has failed to achieve good results. In clinical practice, targeted therapy or chemotherapy is usually the main treatment. The mFOLFOX6 regimen is a standardized regimen for the treatment of advanced CRC. The main drugs in this regimen are oxaliplatin and 5-fluorouracil (5-FU). Patients with advanced CRC combined with standard chemotherapy regimens can achieve a higher resection rate of liver metastases in unresectable patients, which can achieve significant survival improvement. Therefore, in this study, oxaliplatin + calcium folinate + 5-Fu + mFOLFOX6 regimen was combined with cetuximab and simvastatin to treat CRC patients, and the clinical efficacy and prognosis were analyzed, as well as the prognostic factors. The results showed that the addition of simvastatin on the basis of conventional mFOLFOX6 regimen combined with cetuximab chemotherapy could effectively improve the efficacy, reduce the total incidence of adverse reactions, improve the overall survival rate, and prolong the overall survival time of patients. Pathological grade and peritoneal metastasis were the factors affecting the mean survival time of CRC patients.

Highlights

Colorectal cancer (CRC) is one of the most common malignant tumors in China, with a high morbidity and mortality rate [1, 2]
When Kirsten rat sarcoma viral oncogene homolog (K-RAS) gene is mutated, its expression is not regulated by Epidermal growth factor receptor (EGFR) signal, which leads to abnormal proliferation and metastasis of tumor cells, and leads to resistance of patients to EGFR inhibitor drugs [9,10,11,12]
As a common gastrointestinal malignant tumor, CRC lacks specific symptoms at the early stage of onset, so most patients are already in the middle and late stages when diagnosed [17, 18]. e mFOLFOX6 is a standardized regimen for the treatment of advanced CRC, in which oxaliplatin and 5-FU are the main drugs that play a role [19, 20]

Summary

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumors in China, with a high morbidity and mortality rate [1, 2]. K-RAS gene is a downstream signaling molecule of EGFR. When K-RAS gene is mutated, its expression is not regulated by EGFR signal, which leads to abnormal proliferation and metastasis of tumor cells, and leads to resistance of patients to EGFR inhibitor drugs [9,10,11,12]. With the advent of oxaliplatin and irinotecan, new modes of administration, new chemotherapy drugs, and new combination regimens, new breakthroughs have been made in the treatment of metastatic CRC, especially in the aspect of molecular targeted therapy [13, 14]. Patients with advanced CRC combined with standard chemotherapy regimens can achieve a higher resection rate of liver metastases in unresectable patients, which can achieve significant survival improvement. Patients with advanced CRC combined with standard chemotherapy regimens can achieve a higher resection rate of liver metastases in unresectable patients, which can achieve significant survival improvement. erefore, this study treated

Methods

Results

Conclusion